Seven outpatients already receiving neuroleptic drugs by depot intramuscular injections were treated in two consecutive 3-week periods with 25 mg fluphenazine doses as enanthate and decanoate esters in a double-blind crossover study. They were assessed for incidence of akinesia, involuntary movement, autonomic disturbances and drowsiness, using a rating scale, and their blood pressures and pulse rates were recorded. Blood was collected for plasma fluphenazine and plasma prolactin assay. Additionally, a handwriting test was applied. A higher incidence of unwanted drug effects occurred when plasma fluphenazine concentrations were maximal, but this was not so with prolactin concentrations. No significant blood pressure changes occurred. Small increases in pulse rate and decreases in handwriting length occurred, but these changes were not associated with high fluphenazine levels.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Altamura AC, Whelpton R, Curry SH (1979) Animal model for fluphenazine kinetics after administration of long-acting esters. Biopharmaceutics and Drug Disposition 1:65–72
Asberg M, Montgomery S, Perris C, Schalling D, Sedvall G (1978) The Comprehensive Psychopathological Rating Scale. Acta Psychiatr Scand 271s:10–27
Curry SH, Altamura AC, Montgomery SA (1979b) Unwanted effects of enanthate and decanoate. Lancet 1:331–332
Curry SH, Whelpton RW, de Schepper PJ, Vranckx S, Schiff AA (1979a) Kinetics of fluphenazine after fluphenazine dihydrochloride, enanthate and decanoate administration to man. Br J Clin Pharmacol 7:325–331
Kane J, Quitlain F, Rifkin A, Klein DF (1978) Comparison of the incidence and severity of extrapyramidal side effects with fluphenazine enanthate and fluphenazine decanoate. Am J Psychiatr 135:1539–1542
Keskiner A, Itil TM, Holden JMC (1969) Fluphenazine enanthate and decanoate: a comparative study in chronic schizophrenic out-patients. Psychosomatics 10:42–45
Wiles DH, Gelder MG (1979) Plasma fluphenazine levels by radio-immunoassay in schizophrenic patients treated with depot injections of fluphenazine decanoate. Br J Clin Pharmacol 8:565–570
Wiles DH, Kolakowska T, McNeilly AS, Mandelbroke BM, Gelder MG (1976) Clinical significance of plasma chlorpromazine levels. I. Plasma levels of the drug some of its metabolites and prolactin during acute treatment. Psychol Med 6:407–415
About this article
Cite this article
Altamura, A.C., Curry, S.H., Montgomery, S. et al. Early unwanted effects of fluphenazine esters related to plasma fluphenazine concentrations in schizophrenic patients. Psychopharmacology 87, 30–33 (1985). https://doi.org/10.1007/BF00431773
- Long-acting esters
- Side effects
- Double-blind trial